Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Can Japan Become the Global Leader in Drug Discovery? New Vision for Pharmaceutical Industry Drops Company Categories Included in the Previous One
August 15, 2013
- PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
- MHLW Compiles Report on Expert Council on Future Cancer Research
August 14, 2013
- EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
- 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
- Japan NIH HQ to Orchestrate Allocation of 100 Billion Yen for R&D Budgets, Starting with FY2014 Requests
August 12, 2013
- 1st Committee on Drugs to Discuss Pediatric Indication for Kyowa Kirin’s Nesp
August 12, 2013
- MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
- MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
August 9, 2013
- PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
August 8, 2013
- US FDA Advisory Committee Votes Against Approval of Tolvaptan for Treatment of ADPKD
August 8, 2013
- Education Ministry Set Up Task Force for Prevention of Misconduct in Research, Will Discuss Diovan Issue
August 7, 2013
- Gov’t to Establish “Headquarters to Promote Health and Healthcare Strategy” as HQ for Japanese Version of NIH
August 6, 2013
- First Committee on Drugs Recommends Approval for Long-Acting Injectable Schizophrenia Treatment Xeplion
August 6, 2013
- Health Ministry’s Diovan Study Committee to Start on Aug 9, Minister Expects Attendance of Ex-Novartis Employee
August 5, 2013
- EAD Director to Personally Visit Hospitals to Urge Early Price Agreement
August 5, 2013
- Distribution Reform and Perpetuation of Premium for New Drug Development Are Immediate Top-Priority Issues: EAD Director Jo
August 2, 2013
- CSIMC Subcommittee Discusses Revisions of Drug Pricing Rules; Some Reps Oppose Proposed Rewards for Innovation
August 1, 2013
- “No Surprises” in TPP Negotiations; Gov’t Undecided Whether to Hold Briefing for the Drug Industry: PR Counselor Nakagawa
July 31, 2013
- Combination of Insured and Uninsured Treatments to Be a Top Priority Topic in Discussions by Council for Regulatory Reform
July 30, 2013
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…